Study on hypoglycemic mechanism of Qiyu Granules based on UPLC-Q-TOF/MS and network pharmacology
Objective Based on UPLC-Q-TOF/MS and network pharmacology technology,to explore the mechanism of Qiyu Granules in lowering blood sugar.Methods UPLC-Q-TOF/MS technology was used to study the blood entering components of Qiyu Granules,and then the network pharmacology analysis was conducted to construct the component target disease network with the blood entering components as the effective components,to predict the possible mechanism of Qiyu Granules in treating diabetes.And diabetes model was induced by high sugar and high fat diet combined with small dose strep-tozotocin(STZ)to verify the effect of Qiyu Granules on PI3K-Akt-GSK-3β in diabetes rats.Results Through blood component analysis,17 prototype components such as puerarin,astragaloside,albumen and daidzein were identified,and 69 metabolites derived from caffeic acid,puerarin,ferulic acid and daidzein were identified.tumor necrosis factor was obtained through network pharmacological analysis.(tumor necrosis factor,TNF),serine-threonine-protein kinase1(AKT1)and other 98 key targets and 144 pathways such as cancer pathways and insulin resistance were obtained ultimately.After 9 weeks of administration of Qiyu granules,the blood glucose of diabetic rats decreased significantly(P<0.001),phosphoinositide 3-kinase(PI3K),threonine-protein kinase(Threonine-kinase),and Phosphoinositide 3-kinase(PI3K).AKT),phosphorylated glycogen synthase kinase-3β/Glycogen synthase kinase-3β(GSK-3β)(P<0.01,P<0.05,P<0.001)significantly increased.Conclusion The mechanism of Qiyu Granules in preventing and treating diabetes can be predicted by combining serum pharmacochemistry with network pharmacology mining,which provides scientific basis for the study of Qiyu Granules'hypoglycemic mechanism and quality control evaluation.Animal experiments have preliminarily confirmed that Qiyu Granules can prevent and treat diabetes by regulating PI3K-Akt-GSK-3β signal pathway related proteins.
Qiyu Granulesingredient into bloodnetwork pharmacologyPI3K-Akt-GSK-3β signal pathwayhypoglycemic activityUPLC-Q-TOF/MS
NETL
NSTL
万方数据
